Patterns Of Care

Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:Introduction (0:00)HER2 History (1:32)Cases from the GMO Survey (7:06)Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)Faculty Case Presentations (31:37)Patterns of Care Survey — Part 1 (38:26)Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)Faculty Case Presentations (54:13)CME information and select publications

Featuring perspectives from Dr William G Wierda, including the following topics:Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)Sequencing Road Map (12:39)Key Datasets — Pirtobrutinib (21:08)Investigator Survey (34:09)Chimeric Antigen Receptor T-Cell Therapy (45:08)Other Novel Therapy Approaches (49:58)EHA 2026 (54:45)CME information and select publications

Featuring an interview with Prof Ticiana Leal, including the following topics:Pathophysiology and clinical signs and symptoms (0:00)Screening and/or diagnostic approaches (5:45)Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36)Key clinical trial data for amifampridine and practicalities of its administration (14:05)Building awareness among patients, caregivers and the oncology community (22:37)Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35)Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41)Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55)Current research and potential developments in the treatment of SCLC (48:32)CME information and select publications

Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:Introduction (0:00)Overview of Prostate Cancer (3:00)Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)Potential Role of Capivasertib in Metastatic HSPC (27:22)Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)CME information and select publications

Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)First-Line Therapy (PD-L1 Negative) (6:53)First-Line Therapy (PD-L1 Positive) (23:40)Second-Line Therapy (Sequencing) (34:08)Adverse Events with TROP2-Targeting ADCs (43:43)CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A patient with T4 disease, pelvic wall involvement and a positive pelvic node treated as metastatic disease with enfortumab vedotin and pembrolizumab attains a complete response on imaging after 6 cycles (0:00)Case: A man with muscle-invasive bladder cancer who receives neoadjuvant chemotherapy with durvalumab receives positive circulating tumor DNA results before cystectomy and negative results after surgery (7:41)CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A man in his early 80s with non-muscle-invasive bladder cancer (NMIBC) monitored by repeat TURBTs develops localized muscle-invasive bladder cancer and enrolls in a clinical trial of neoadjuvant enfortumab vedotin with pembrolizumab (0:00)Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (CIS) receives BCG induction and experiences relapse of CIS during BCG maintenance (9:24)CME information and select publications

Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:Introduction: Lymphoma Survivorship (0:00)Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)CME information and select publications

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:Introduction (0:00)Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)Utility of Tumor Treating Fields in PAD Management (1:13:58)CME information and select publications

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:Introduction: San Antonio Memories (0:00)PI3K/AKT/PTEN Alterations and Therapies (7:18)Capivasertib (20:22)Gedatolisib (34:08)Inavolisib (47:07)New Agents and Ongoing Trials (52:34)CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00)Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29)CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00)Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26)CME information and select publications

Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics:Introduction (00:00)Biomarker Evaluation in Localized and Metastatic Disease (1:49)Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37)Other Available Therapeutic Approaches — Dr Shitara (33:22)CME information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics:Introduction: Welcome GU Oncology Fellows! (0:00)Prostate Cancer — Dr Aggarwal (12:48)Urothelial Bladder Cancer — Dr Galsky (45:01)Renal Cell Carcinoma — Dr Zhang (1:10:52)CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics:Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00)Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00)Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40)CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics:Introduction (0:00)Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37)Practical Considerations with Oral SERDs (15:43)Potential Role of Combination Approaches with Oral SERDs (26:33)Gastrointestinal Adverse Events Documented with Oral SERDs (38:19)Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:54)Other Class-Effect Toxicities Associated with Oral SERDs (1:00:56)Emerging Utility of Adjuvant Oral SERDs (1:10:20)Unique Toxicities Associated with 1 or More Oral SERDs (1:19:22)CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics:Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00)Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops neuropathy, discontinues the EV and continues pembrolizumab with no toxicity — Catherine Fahey, MD, PhD (12:01)Case: A woman in her late 50s with metastatic UBC receives EV with pembrolizumab on a clinical trial and experiences a response but develops diarrhea and pruritus — Fern Anari, MD (21:43)CME information and select publications

Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:Introduction (00:00)Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)ASCO and EHA 2026 (46:37)CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A woman in her late 60s with T3N0 upper tract urothelial carcinoma that was resected has no evidence of disease on imaging, receives negative circulating tumor DNA results and elects observation instead of adjuvant treatment (0:00)Case: A man in his late 70s with PD-L1-negative high-grade muscle-invasive bladder cancer who is ineligible for cisplatin because of poor renal function undergoes cystectomy (10:12)CME information and select publications

Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A healthy man in his early 70s who received several different lines of therapy for non-muscle-invasive bladder cancer (NMIBC), wants to avoid radical cystectomy and does not want pembrolizumab (0:00)Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (11:20)CME information and select publications